Subject: Re: Pfizer a permanent presence
I had a further dig into Pfizer and think it'll flat line too. It's just retreating back to pre pandemic levels IMO. Ie where we see EPS between $2.50 and $3 over the next 5 years and a low multiple of earnings which reflects this. Quality of earnings and growth are of paramount importance to avoid value traps and something I'm concentrating more on now when scrutinizing super investor buys.